These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 957112)

  • 1. Binding characteristics of drugs to synthetic levodopa melanin.
    Shimada K; Baweja R; Sokoloski T; Patil PN
    J Pharm Sci; 1976 Jul; 65(7):1057-60. PubMed ID: 957112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding characteristics of fluoroquinolones to synthetic levodopa melanin.
    Ono C; Tanaka M
    J Pharm Pharmacol; 2003 Aug; 55(8):1127-33. PubMed ID: 12956903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevance of drug-melanin interactions to ocular pharmacology and toxicology.
    Salazar-Bookaman MM; Wainer I; Patil PN
    J Ocul Pharmacol; 1994; 10(1):217-39. PubMed ID: 8207328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Affinity of drugs for dopa-auto-oxidation melanin and tyrosinase-catalyzed dopa-melanin in vitro.
    Hayasaka S; Tsuchiya M; Noda S; Setogawa T; Mizuno K
    Ophthalmic Res; 1988; 20(6):376-9. PubMed ID: 3148876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Phototoxicity Testing Strategy for Accurate Photosafety Evaluation of Pharmaceuticals Based on the Assessment of Possible Melanin-Binding Effects.
    Reinen J; van Sas P; van Huygevoort T; Rubio L; Scase K; Wenker M
    Int J Toxicol; 2018; 37(4):296-307. PubMed ID: 29898631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cocaine, benzoylecgonine, amphetamine, and N-acetylamphetamine binding to melanin subtypes.
    Borges CR; Roberts JC; Wilkins DG; Rollins DE
    J Anal Toxicol; 2003 Apr; 27(3):125-34. PubMed ID: 12731652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affinity of ocular acid-insoluble melanin for drugs in vitro.
    Tsuchiya M; Hayasaka S; Mizuno K
    Invest Ophthalmol Vis Sci; 1987 May; 28(5):822-5. PubMed ID: 3570692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of memantine to melanin: influence of type of melanin and characteristics.
    Koeberle MJ; Hughes PM; Skellern GG; Wilson CG
    Pharm Res; 2003 Oct; 20(10):1702-9. PubMed ID: 14620529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation by NMR spectroscopy of the interaction between synthetic soluble (-)-dopa melanin and drugs.
    Salazar-Bookaman MM; Fowble J; Weber P; Patil PN
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Nov; 340(5):576-82. PubMed ID: 2515443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of drugs to eye melanin is not predictive of ocular toxicity.
    Leblanc B; Jezequel S; Davies T; Hanton G; Taradach C
    Regul Toxicol Pharmacol; 1998 Oct; 28(2):124-32. PubMed ID: 9927562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding affinity of bunazosin, dorzolamide, and timolol to synthetic melanin.
    Kiuchi Y; Terakawa N; Nakata T; Yamasaki K; Saito Y; Ito N; Okada K
    Jpn J Ophthalmol; 2004; 48(1):34-6. PubMed ID: 14767648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of protoporphyrin to melanin and oxidation-reduction properties of melanin-protoporphyrin complex.
    Persad S; Haberman HF; Menon IA
    Can J Biochem; 1981 Apr; 59(4):269-72. PubMed ID: 7248838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of affinity chromatography to the study of drug-melanin binding interactions.
    Aubry AF
    J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Feb; 768(1):67-74. PubMed ID: 11939559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of chemicals to melanins re-examined: adsorption of some drugs to the surface of melanin particles.
    Bridelli MG; Ciati A; Crippa PR
    Biophys Chem; 2006 Jan; 119(2):137-45. PubMed ID: 16139945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanosome binding and oxidation-reduction properties of synthetic L-dopa-melanin as in vitro tests for drug toxicity.
    Debing I; Ijzerman AP; Vauquelin G
    Mol Pharmacol; 1988 Apr; 33(4):470-6. PubMed ID: 3357487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Competitive binding between cocaine and various drugs to synthetic levodopa melanin.
    Baweja R; Sokoloski TD; Patil PN
    J Pharm Sci; 1977 Nov; 66(11):1544-7. PubMed ID: 915728
    [No Abstract]   [Full Text] [Related]  

  • 17. Studies on the melanin affinity of selegiline (deprenyl) and other amphetamine derivatives.
    Báthory G; Szüts T; Magyar K
    Pol J Pharmacol Pharm; 1987; 39(2):195-201. PubMed ID: 3124086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of drug binding to melanin using a melanin-based high-performance liquid chromatographic stationary phase and chemometric analysis of the chromatographic data.
    Kaliszan R; Kaliszan A; Wainer IW
    J Chromatogr; 1993 Jun; 615(2):281-8. PubMed ID: 8335705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interaction of L-DOPA melanin with p-tert-butylcatechol.
    Menter JM; Willis I
    J Invest Dermatol; 1980 Sep; 75(3):257-60. PubMed ID: 7410892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of the mechanism of chloroquine binding to synthetic DOPA-melanin.
    Stepień KB; Wilczok T
    Biochem Pharmacol; 1982 Nov; 31(21):3359-65. PubMed ID: 6816244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.